Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRA
- Conditions
- Covid 19.COVID 19, virus identifiedU07.1
- Registration Number
- IRCT20210620051639N3
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10300
Age 18 years and older
Candidates who have received two identical doses of the available vaccine (Sinopharm, CovIran Barakat, AstraZenka) and at least 3 months (at least 90 days) have passed since the second dose
The candidate is able to fully understand the provisions of the informed consent form and sign it before entering the study
SARS CoV 2 infection (clinically significant or rtPCR document)
Approved or suspected COVID 19 in the last two months
Going through home quarantine due to suspicion of having an exposure to a patient with Corona
History of severe allergic reactions
Chronic kidney, liver and various malignancies
Acute bacterial infection in the last 7 days
Known cases of immunodeficiency, HIV, or autoimmune diseases
Receiving immunosuppressive drugs or corticosteroids in the last 3 months
Receiving immunoglobulin or blood products during the three months prior to vaccination
Pregnant or Breastfeeding women or those who plan to become pregnant during the study period
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method